Inhibition of in vitro spontaneous apoptosis by IL-7 correlates, with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia

Blood

Volumn 96, Issue 1, 2000, Pages 297-306

  Karawajew, Leonid ^a   Ruppert, Velia ^b   Wuchter, Christian ^b   Kösser, Annett ^b   Schrappe, Martin ^b   Dörken, Bernd ^b   Ludwig, Wolf Dieter ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; PROTEIN BAX; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE;

EID: 0034235117     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.297.013k24_297_306     Document Type: Article

References (69)

1. Park JR. Cytokine regulation of apoptosis in hematopoietic precursor cells. Curr Opin Hematol. 1996;3:191.
2. Williams DE, Fletcher FA, Lyman SD, de Vries P. Cytokine regulation of hematopoietic stem cells. Semin Immunol 1991;3:391.
3. Zlotnik A, Moore TA. Cytokine production and requirements during T-cell development. Curr Opin Immunol. 1995;7:206.
4. DiSanto JP, Muller W, Guy Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1995; 92:377.
5. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73:147.
6. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 1991;352:621.
7. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science. 1991;254:707.
8. Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med. 1994;180:1955.
9. von Freeden Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med. 1995;181: 1519.
10. Plum J, De Smedt M, Leclercq G, Verhasselt B, Vandekerckhove B. Interleukin-7 is a critical growth factor in early human T-cell development. Blood. 1996;88:4239.
11. Akashi K, Kondo M, von Freeden Jeffry U, Murray R, Weissman IL. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 1997;89:1033.
12. Kim K, Lee CK, Sayers TJ, Muegge K, Durum SK. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of pro-T1, -T2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol. 1998;160:5735.
13. McCulloch EA. Stem cell renewal and determination during clonal expansion in normal and leukaemic haemopoiesis. Cell Prolif. 1993;26:399.
14. Dibirdik I, Langlie MC, Ledbetter JA, et al. Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turn-over, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. Blood. 1991; 78:564.
15. Makrynikola V, Kabral A, Bradstock K. Effects of interleukin 7 on the growth of clonogenic cells in T-cell acute lymphoblastic leukaemia. Leuk Res. 1991;15:879.
16. Masuda M, Takanashi M, Motoji T, Oshimi K, Mizoguchi H. Effects of interleukins 1-7 on the proliferation of T-lineage acute lymphoblastic leukemia cells. Leuk Res. 1991;15:1091.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451.
18. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783.
19. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898.
20. Creutzig U, Harbott J, Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 1995;86:3097.
21. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia [letter; comment], J Clin Oncol. 1996; 14:2403.
22. Vella AT, Dow S, Potter TA, Kappler J, Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci U S A. 1998; 95:3810.
23. Skjonsberg C, Erikstein BK, Smeland EB, et al. Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias Blood. 1991;77:2445.
24. Karawajew L, Wuchter C, Ruppert V, et al. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia. 1997;11:1245.
25. Lisovsky M, Estrov Z, Zhang X, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996;88:3987.
26. Dive C, Gregory CD, Phipps DJ, Evans DL, Milner AE, Wyllie AH. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim Biophys Acta. 1992;1133:275.
27. Suda T, Zlotnik A. IL-7 maintains the T cell precursor potential of CD3-CD4-CD8-thymocytes. J Immunol. 1991;146:3068.
28. Fischer M, MacNeil I, Suda T, Cupp JE, Shortman K, Zlotnik A. Cytokine production by mature and immature thymocytes. J Immunol. 1991;146:3452.
29. Migliorati G, Nicoletti I, Pagliacci MC, D'Adamio L, Riccardi C. Interleukin-2 induces apoptosis in mouse thymocytes. Cell Immunol. 1993;146:52.
30. Erb KJ, Hanke T Schimpl A, Hunig T, Stingl G, Elbe A. Impaired survival of T cell receptor V gamma 3+ cells in interleukin-4 transgenic mice. Eur J Immunol. 1995;25:1442.
31. Genestier L, Paillot R, Bonnefoy Berard N, Waldmann H, Revillard JP. T cell sensitivity to HLA class 1-mediated apoptosis is dependent on interleukin-2 and interleukin-4. Eur J Immunol. 1997; 27:495.
32. Manabe A, Coustan Smith E, Kumagai M, et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood. 1994;83:1731.
33. Smiers FJ, van Paassen M, Pouwels K, et al. Heterogeneity of proliferative responses of human B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells to interleukin 7 (IL-7): no correlation with immunoglobulin gene status and expression of IL-7 receptor or IL-2/IL-4/IL-7 receptor common gamma chain genes. Leukemia. 1995;9:1039.
34. Cerezo A, Martinez AC, Gonzalez A, Gomez J, Rebollo A. IL-2 deprivation triggers apoptosis which is mediated by c-Jun N-terminal kinase 1 activation and prevented by Bcl-2. Cell Death Differ. 1999;6:87.
35. Hockenbery D, Nunez G. Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;48:334.
36. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609.
37. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379.
38. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol. 1996;156:2624.
39. Tangye SG, Raison RL. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol. 1997;75:127.
40. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics Leukemia. 1999;13:1943.
41. Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoplosis in childhood acute lymphoblastic leukemia. Blood. 1997;89:2986
42. Akbar AN, Borthwick NJ, Wickremasinghe RG, et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol. 1996;26:294.
43. Kinoshita T, Yokota T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signaling through the IL-3/GM-CSF receptors. EMBO J. 1995;14:266.
44. Lee SH, Fujita N, Mashima T, Tsuruo T. Interleukin-7 inhibits apoptosis of mouse malignant T-lymphoma cells by both suppressing the CPP32-like protease activation and inducing the Bcl-2 expression. Oncogene. 1996;13:2131.
45. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76:935.
46. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996;12:1055.
47. Stoetzer OJ, Nussler V, Darsow M, et al. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia. 1996;10(suppl 3):S18.
48. von Freeden Jeffry U, Solvason N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity. 1997;7:147.
49. Nakayama K, Nakayama K, Negishi I, et al. Dis-appearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science. 1993; 261:1584.
50. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90:2723.
51. Smith BD, Bambach BJ, Vala MS, et al. Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br J Haematol. 1998;102:1042.
52. Uckun FM, Yang Z, Sather H, et al. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood. 1997;89:3769.
53. Barnes PJ. Anti-inflammatory mechanisms of glucocorticoids. Biochem Soc Trans. 1995;23:940.
54. Chresta CM, Arriola EL, Hickman JA. Apoptosis and cancer chemotherapy. Behring Inst Mitt. 1996;232.
55. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845.
56. Greaves MF, Chan LC, Furley AJ, Watt SM, Molgaard HV. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986;67:1.
57. Greaves MF. Stem cell origins of leukaemia and curability. Br J Cancer. 1993;67:413.
58. Uckun FM, Tuel Ahlgren L, Obuz V, et al. Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. Proc Natl Acad Sci U S A. 1991;88:6323.
59. Pallard C, Stegmann AP, van Kleffens T, Smart F, Venkitaraman A, Spits H. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity. 1999;10:525.
60. Hofmeister R, Khaled AR, Benbernou N, Rajnavolgyi E, Muegge K, Durum SK. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev. 1999;10:41.
61. Laky K, Lefrancois L, von Freeden Jeffry U, Murray R, Puddington L. The role of IL-7 in thymic and extrathymic development of TCR gamma delta cells. J Immunol. 1998;161:707.
62. Maki K, Sunaga S, Ikuta K. The V-J recombination of T cell receptor-gamma genes is blocked in interleukin-7 receptor-deficient mice. J Exp Med. 1996;184:2423.
63. Schott G, Sperling C, Schrappe M, et al. Immunophenotypic and clinical features of T-cell teceptor gamma/delta+ T-lineage acute lymphoblastic leukaemia. Br J Haematol. 1998;101:753.
64. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91:735.
65. Ludwig WD, Harbott J, Bartram CR, et al. Incidence and prognostic significance of immuno-phenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results Cancer Res. 1993;131:269.
66. Schrappe M, Sperling C, Reiter A, et al. In vivo sensitivity of childhood T-cell ALL is the most relevant prognostic marker independent of maturational stage [abstract]. Blood. 1998;92:397a.
67. Niehues T, Kapaun P, Harms DO, et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia. 1999;13:614.
68. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol. 1996;14:389.
69. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717.